Takahara, Mitsuyoshi
Fukuda, Masahiro
Matsuzawa, Yuji
Shimomura, Iichiro
Funding for this research was provided by:
LOTTE Co., Ltd., Tokyo, Japan
Article History
Received: 13 December 2019
Accepted: 27 March 2020
First Online: 11 April 2020
Compliance with ethical standards
:
: Mitsuyoshi Takahara is a staff member of the endowed chair (Department of Diabetes Care Medicine) which received funds from AstraZeneca K.K., Mitsubishi Tanabe Pharma Co., MSD K.K., Nippon Boehringer Ingelheim Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., and Taisho Toyama Pharmaceutical Co.. Masahiro Fukuda has received honoraria from Mitsubishi Tanabe Pharma Co., MSD K.K., Ono Pharmaceutical Co., Sanofi K.K., and Takeda Pharmaceutical Co., and has received research funding from Astellas Pharma, LOTTE Co., Novo Nordisk Pharma, and Sanofi K.K.. Yuji Matsuzawa declares that he has no conflict of interest. Iichiro Shimomura has received honoraria from Astellas Pharma, Eli Lilly Japan K.K., Kowa Co., Mitsubishi Tanabe Pharma Co., MSD K.K., Nippon Boehringer Ingelheim Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., and Takeda Pharmaceutical Co., and has received subsides or donations from Astellas Pharma, AstraZeneca K.K., Daiichi Sankyo Co., Kowa Co., Kyowa Kirin Co., Mitsubishi Tanabe Pharma Co., MSD K.K., Novartis Pharmaceuticals Corp., Novo Nordisk Pharma, Ono pharmaceutical Co., Sanofi K.K., Sumitomo Dainippon Pharma., Takeda Pharmaceutical Co., Teijin Pharma, and Terumo Corporation.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.